热门资讯> 正文
Cogent获得贝祖拉替尼FDA突破治疗地位
2025-10-21 05:21
- The US FDA has granted Breakthrough Therapy designation for Cogent Biosciences' bezuclastinib for NonAdvanced Systemic Mastocytosis and Smoldering Systemic Mastocytosis.
- The company plans an NDA submission for the first indication by the end of the year.
- Breakthrough Therapy status was granted based on results from the SUMMIT trial that were released in July. Data showed bezuclastinib met its primary endpoint, a highly statistically significant difference in the mean change in total symptom score (TSS) at 24 weeks versus placebo. Participants in the bezuclastinib arm demonstrated a mean reduction of 24.3 points in TSS at 24 weeks, compared to 15.4 points in the placebo cohort.
More on Cogent Biosciences
- Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript
- Cogent Biosciences: Moving Forward
- Seeking Alpha’s Quant Rating on Cogent Biosciences
- Historical earnings data for Cogent Biosciences
- Financial information for Cogent Biosciences
推荐文章
华盛早报 | 美股全线大跌！OpenAI高管发言引发"AI圈"风暴；马斯克拿下“万亿薪酬包”
AI应用概念股财报大PK：绩后陷“冰火两重天”，哪些公司经受住了考验？
美股机会日报 | 马斯克能否留下？万亿美元薪酬方案投票即将揭晓；英伟达黄仁勋：中国将赢得人工智能竞赛！
美股七巨头Q3成绩单：砸钱不手软！科技巨头狂投AI；英伟达尚未公布业绩，已是最大赢家？
华盛早报 | 特朗普：将尽快结束停摆，美股有望再创新高！绩后股价剧烈分化：Rivian大涨23.36%，多邻国、Pinterest大跌20%
美股机会日报 | 停摆已达36天！美政府停摆时间创史上最长纪录；就业风向标“小非农”今晚公布
11月财报预告 | 明星科网股财报在即！英伟达、腾讯控股、京东等巨头将发财报，谁将带来惊喜？
一周财经日历 | 美国政府继续停摆，大小非农能否如期发布？IPO火爆，6只港股即将上市；美股进入冬令时
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
